STIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Neuronetics's EBITDA per Share for the three months ended in Sep. 2024 was $-0.37.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Neuronetics was 89.40% per year. The lowest was 7.10% per year. And the median was 25.10% per year.
For the Diagnostics & Research subindustry, Neuronetics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Neuronetics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Neuronetics (NAS:STIM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Neuronetics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Furlong | officer: CFO | C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355 |
William Andrew Macan | officer: Sr. VP, GC, CCO and Secretary | 24275 KATY FREEWAY, SUITE 600, KATY TX 77494 |
Robert Cascella | director | C/O HOLOGIC, INC., BEDFORD MA 01730 |
Glenn P Muir | director | C/O HOLOGIC, INC., BEDFORD MA 01730 |
Keith J Sullivan | director, officer: President and CEO | C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043 |
John K Bakewell | director | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862 |
Cannell Capital Llc | 10 percent owner | 245 MERIWETHER CIRCLE, ALTA WY 83414 |
Joseph H Capper | director | BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355 |
Bruce Joseph Shook | director | 162 CRICKET AVE, ARDMORE PA 19003 |
Megan Rosengarten | director | C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355 |
Sheryl L Conley | director | C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355 |
Wilfred E Jaeger | director | C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028 |
Gregory Harper | officer: VP of Prod. Dev. & Operations | C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355 |
Brian E Farley | director | 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131 |
Daniel Guthrie | officer: Chief Commercial Officer | C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355 |
From GuruFocus
By GuruFocus Research • 08-14-2024
By Marketwired • 09-16-2024
By Marketwired • 08-20-2024
By Marketwired • 07-11-2024
By Marketwired • 08-05-2024
By Marketwired • 10-29-2024
By GuruFocus News • 11-13-2024
By GuruFocus Research • 08-14-2024
By Marketwired • 07-31-2024
By Marketwired • 08-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.